Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000672436 | SCV000797541 | uncertain significance | Metachromatic leukodystrophy | 2018-02-05 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000672436 | SCV000915007 | uncertain significance | Metachromatic leukodystrophy | 2018-03-05 | criteria provided, single submitter | clinical testing | The ARSA c.251C>T (p.Pro84Leu) missense variant, historically described as p.Pro82Leu, has been reported two in studies. Barth et al. (1995) describe a child with late infantile arylsulfatase A deficiency, also known as metachromatic leukodystrophy, in whom the p.Pro84Leu variant was identified in a heterozygous state. A second variant was not detected. In 2008, Biffi et al. reported a child with early juvenile arylsulfatase A deficiency in whom the p.Pro84Leu was identified in trans with a second missense variant. The p.Pro84Leu variant was absent from 110 control chromosomes from healthy individuals, and is reported at a frequency of 0.000077 in the European (non-Finnish) population of the Exome Aggregation Consortium. Based on the limited evidence, the p.Pro84Leu variant is classified as unknown significance but suspicious for pathogenicity for arylsulfatase A deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
Invitae | RCV000672436 | SCV000947341 | pathogenic | Metachromatic leukodystrophy | 2023-11-02 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 84 of the ARSA protein (p.Pro84Leu). This variant is present in population databases (rs6151411, gnomAD 0.004%). This missense change has been observed in individual(s) with metachromatic leukodystrophy (PMID: 18786133, 28762252, 31694723). ClinVar contains an entry for this variant (Variation ID: 556430). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSA protein function with a positive predictive value of 95%. This variant disrupts the p.Pro84 amino acid residue in ARSA. Other variant(s) that disrupt this residue have been observed in individuals with ARSA-related conditions (PMID: 30057904), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000672436 | SCV002021437 | likely pathogenic | Metachromatic leukodystrophy | 2021-01-26 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000672436 | SCV002548049 | pathogenic | Metachromatic leukodystrophy | 2022-05-12 | criteria provided, single submitter | clinical testing | Variant summary: ARSA c.251C>T (p.Pro84Leu) results in a non-conservative amino acid change located in the Sulfatase, N-terminal domain (IPR000917) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.7e-05 in 229438 control chromosomes (gnomAD). c.251C>T has been reported in the literature in multiple compound heterozygous individuals affected with Metachromatic Leukodystrophy (e.g. Biffi_2008, van Rappard_2016, Bohringer_2017, Hettiarachchi_2019, Beeerepoot_2020). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four ClinVar submitters have assessed the variant since 2014: three classified the variant as of uncertain significance and one as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |